"RIV/68378050:_____/04:00105304!RIV/2005/AV0/A23005/N" . "1019-6439" . . "1"^^ . . "5"^^ . . . "Sn\u00ED\u017Een\u00E1 exprese MHC 1. t\u0159\u00EDdy: \u00FAnik n\u00E1dor\u016F z imunitn\u00ED kontroly?"@cs . "It is suggested that MHC class I down-regulation can, under some conditions, be a mechanism of the tumour escape from the immune defence. The therapeutic procedures aiming at up-regulation of MHC class I expression, or enhancement of MHC class I-unrestricted (CD4+, NK, NKT, gamma-delta T) tumour defence effector mechanisms by dendritic cell-based therapeutic vaccines, by cytokines (IL-2, IL-12, IFNgamma, GM-CSF), or by the cytokine gene-based, genetically modified tumour vaccines should be considered" . "P(GA301/04/0492), P(IAA5052203), P(NC7148), Z(AV0Z5052915)" . "[54ACD5471BF6]" . . "RIV/68378050:_____/04:00105304" . "MHC class I down-regulation: Tumour escape from immune surveillance? (Review)"@en . "487;491" . "International Journal of Oncology" . . . "P\u0159edpokl\u00E1d\u00E1 se, \u017Ee sn\u00ED\u017Een\u00E1 exprese MHC 1. t\u0159\u00EDdy m\u016F\u017Ee za ur\u010Dit\u00FDch okolnost\u00ED b\u00FDt mechanismem pro \u00FAnik n\u00E1dor\u016F p\u0159ed imunitn\u00ED obranou. M\u011Bly by b\u00FDt zv\u00E1\u017Eeny l\u00E9\u010Debn\u00E9 postupy zam\u011B\u0159en\u00E9 na zv\u00FD\u0161en\u00ED exprese MHC 1. t\u0159\u00EDdy \u010Di na pos\u00EDlen\u00ED efektorov\u00FDch mechanism\u016F obrany proti n\u00E1dor\u016Fm neomezen\u00FDm MHC 1. t\u0159\u00EDdy (CD4+, NK, NKT, gama-delta T), nebo na vyu\u017Eit\u00ED geneticky modifikovan\u00FDch n\u00E1dorov\u00FDch vakc\u00EDn zalo\u017Een\u00FDch na genech pro cytokiny"@cs . . "GR - \u0158eck\u00E1 republika" . "Sn\u00ED\u017Een\u00E1 exprese MHC 1. t\u0159\u00EDdy: \u00FAnik n\u00E1dor\u016F z imunitn\u00ED kontroly?"@cs . "Buben\u00EDk, Jan" . . . "MHC class I down-regulation: Tumour escape from immune surveillance? (Review)"@en . . "MHC class I down-regulation: Tumour escape from immune surveillance? (Review)" . . "2" . . . "It is suggested that MHC class I down-regulation can, under some conditions, be a mechanism of the tumour escape from the immune defence. The therapeutic procedures aiming at up-regulation of MHC class I expression, or enhancement of MHC class I-unrestricted (CD4+, NK, NKT, gamma-delta T) tumour defence effector mechanisms by dendritic cell-based therapeutic vaccines, by cytokines (IL-2, IL-12, IFNgamma, GM-CSF), or by the cytokine gene-based, genetically modified tumour vaccines should be considered"@en . . . "25" . "1"^^ . . "573448" . "MHC class I- tumour cells; immune surveillance"@en . "MHC class I down-regulation: Tumour escape from immune surveillance? (Review)" . .